<DOC>
	<DOCNO>NCT02201329</DOCNO>
	<brief_summary>To identify maximum tolerate dose recommend dose development volasertib combination azacitidine Japanese patient myelodysplastic syndrome chronic myelomonocytic leukemia , evaluate safety tolerability , pharmacokinetics preliminary efficacy combination .</brief_summary>
	<brief_title>Volasertib Combination With Azacitidine Japanese Patients With Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients age &gt; =20 &lt; =80 year 2 . Patients primary treatmentrelated myelodysplastic syndrome ( MDS ) chronic myelomonocytic leukemia ( CMML ) , eligible hematopoietic stem cell transplantation base investigator 's judgment , meet one follow criterion : Intermediate2 highrisk MDS accord International Prognostic Scoring System , set 530 % bone marrow blast CMML &gt; = 10 % marrow blast without myeloproliferative disorder ( white blood cell count &lt; 13,000/ ÂµL ) 3 . Patients prior azacitidine treatment , prior azacitidine treatment meet one follow criterion : Patients fail achieve haematological improvement , partial remission , marrow complete remission complete remission 3 cycle azacitidine progressed time start azacitidine Patients achieve initial response subsequently develop disease progression relapse 4 . Eastern Cooperative Oncology Group performance status score 0 1 screen 5 . Signed write informed consent consistent Good Clinical Practice . Exclusion criterion : 1 . Treatment systemic therapy MDS , include investigational drug , within 14 day first dose study treatment , except lenalidomide within 12 week first dose study treatment , lack recovery acute toxicity pertinent prior systemic therapy . 2 . Prior treatment volasertib 3 . Contraindications azacitidine treatment accord manufacturer 's product information 4 . Known hypersensitivity trial drug excipients 5 . Concomitant malignancy currently require active therapy ( except hormonal/antihormonal treatment , e.g . prostate breast cancer ) 6 . QTcF prolongation &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) . 7 . Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) relate Gilbert 's syndrome , hemolysis , secondary MDS screen 8 . Aspartate amino transferase alanine amino transferase &gt; 2.5 x ULN 9 . Serum creatinine &gt; 1.5 x ULN screen 10 . Arterial oxygen pressure &lt; 60 torr arterial oxygen saturation &lt; 92 % ( room air ) 11 . Active hepatitis B hepatitis C , laboratory evidence hepatitis positive result hepatitis B surface antigen and/or hepatitis C antibody . 12 . Human immunodeficiency virus infection . 13 . Severe illness organ dysfunction involve heart , lung , kidney , liver organ system , opinion investigator would interfere evaluation safety study treatment include ; infection require active treatment , poorly control ventricular/atrial tachyarrhythmia , use heart pacer , unstable angina pectoris , history myocardial infarction severe congestive heart failure , clinically unstable cardiac pulmonary disease 14 . Any significant concurrent psychiatric disorder social situation accord investigator 's judgment would compromise patient 's safety compliance , interfere consent , study participation , interpretation study result 15 . All male patient female patient child bear potential unwilling use medically acceptable method contraception trial least 6 month end study treatment ( i.e . hormonal contraception , intrauterine device , condom spermicide , etc. ) . Note : female consider child bear potential unless surgically sterilize postmenopausal ( complete absence menses least 12 month without medical reason ) . 16 . Pregnant nursing female patient 17 . Known suspect active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>